Validation of a Sensitive Flow Cytometry Assay to Assess Minimal Residual Disease of Multiple Myeloma Cells in Apheresis Product

被引：0
|
作者：
Jones, Nicholas [1 ]
Ragheb, Josette William [2 ]
Ngo, Brian [1 ]
Uyeji, David [2 ]
Hii, Anselm L. [2 ]
机构：
[1] NeoGen Labs Inc, Pharma Serv, Aliso Viejo, CA USA
[2] NeoGen Labs Inc, Aliso Viejo, CA USA
来源：
BLOOD | 2018年 / 132卷
关键词：
D O I：
10.1182/blood-2018-99-119858
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
5646
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Minimal residual disease in multiple myeloma: Benefits of flow cytometry
    Galtseva, I. V.
    Davydova, Y. O.
    Kapranov, N. M.
    Julhakyan, H. L.
    Mendeleeva, L. P.
    INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY, 2018, 40 (01) : 12 - 20
  • [2] Impact of Minimal Residual Disease in Apheresis Product (aMRD) Assessed by Multiparametric Flow Cytometry (MFC) in Transplant-Eligible Multiple Myeloma (MM) Patients
    Puertas, Borja
    Alejo, Elena
    Rey-Bua, Beatriz
    Perez-Moran, Jose Juan
    Flores-Montero, Juan
    Vidriales-Vicente, Maria Belen
    Agullo, Cristina
    Fonseca-Santos, Marta
    Lopez-Parra, Miriam
    Davila-Vals, Julio
    Garcia-Martin, Luis
    Aguilar-Franco, Carlos
    Alonso-Alonso, Jose Maria
    Garcia-Mateo, Aranzazu
    Serra-Toral, Fe
    Cantalapiedra, Alberto
    Garcia-Coca, Alfonso
    Escalante-Barrigon, Fernando
    Lopez-Corral, Lucia
    Gutierrez-Gutierrez, Norma C.
    Garcia-Sanz, Ramon
    Mateos Manteca, Maria-Victoria
    Puig, Noemi
    Gonzalez-Calle, Veronica
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S143 - S143
  • [3] Minimal Residual Disease Detection by Flow Cytometry in Multiple Myeloma: Why and How?
    Roshal, Mikhail
    SEMINARS IN HEMATOLOGY, 2018, 55 (01) : 4 - 12
  • [4] Regulatory Perspective on Minimal Residual Disease Flow Cytometry Testing in Multiple Myeloma
    Gormley, Nicole J.
    Turley, Danielle M.
    Dickey, Jennifer S.
    Farrell, Ann T.
    Reaman, Gregory H.
    Stafford, Elizabeth
    Carrington, Lea
    Marti, Gerald E.
    CYTOMETRY PART B-CLINICAL CYTOMETRY, 2016, 90 (01) : 73 - 80
  • [5] Minimal residual disease monitoring in multiple myeloma: flow cytometry is the method of choice
    Owen, RG
    Rawstron, AC
    BRITISH JOURNAL OF HAEMATOLOGY, 2005, 128 (05) : 732 - 733
  • [6] MINIMAL RESIDUAL DISEASE MONITORING IN MULTIPLE MYELOMA USING POLYCHROMATIC FLOW CYTOMETRY
    Rihova, Lucie
    Varmuzova, Tamara
    Zarbochova, Pavla
    Suska, Renata
    Penka, Miroslav
    Hajek, Roman
    CYTOMETRY PART B-CLINICAL CYTOMETRY, 2012, 82B (06) : 404 - 405
  • [7] Minimal residual disease testing in multiple myeloma by flow cytometry: major heterogeneity
    Flanders, Aaron
    Stetler-Stevenson, Maryalice
    Landgren, Ola
    BLOOD, 2013, 122 (06) : 1088 - 1089
  • [8] Adaptation of a multiple myeloma minimal residual disease multicolor flow cytometry assay for real-world practice
    McMillan, Annabel
    Thien-An Tran
    Galas-Filipowicz, Daria
    Camilleri, Marquita
    Lecat, Catherine
    Ainley, Louise
    Guo, Yanping
    Yong, Kwee
    Sive, Jonathan
    CYTOMETRY PART B-CLINICAL CYTOMETRY, 2023, 104 (04) : 304 - 310
  • [9] Reliable monitoring of minimal residual disease in multiple myeloma:: how specific is flow cytometry?
    Lioznov, MV
    Cortes-Dericks, L
    Fehse, B
    Zander, AR
    Kröger, N
    BONE MARROW TRANSPLANTATION, 2006, 37 : S146 - S147
  • [10] NEW STRATEGIES OF ANALYSIS WITH FLOW CYTOMETRY FOR THE DIAGNOSIS OF MINIMAL RESIDUAL DISEASE IN MULTIPLE MYELOMA
    Beneit, P.
    Tarin, F.
    Mora, E.
    Villarrubia, B.
    Mauricio, A.
    Fernandez, Ma
    Salazar, S.
    Jose De Paz, F.
    Verdu, J.
    Sanchez, S.
    Sanchez-Majano, J.
    Castano, V.
    Fernandez, C.
    Blanes, M.
    Verdu, J. Juan V.
    HAEMATOLOGICA, 2013, 98 : 314 - 314
12345